Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
3.810
-0.180 (-4.51%)
Nov 16, 2026, 4:00 PM EST - Market closed

Vanda Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
229.28216.11198.77192.64254.38268.68
Revenue Growth
8.11%8.72%3.18%-24.27%-5.32%8.27%
Cost of Revenue
14.713.0411.3114.824.2825.63
Gross Profit
214.57203.06187.46177.84230.1243.05
Selling, General & Admin
262.75237.95146.41112.88136.49124.05
Research & Development
122.02109.2774.4376.8285.7775.36
Amortization of Goodwill & Intangibles
7.717.017.272.091.521.48
Operating Expenses
392.48354.23228.12191.8223.77200.89
Operating Income
-177.91-151.17-40.66-13.956.3342.17
Interest & Investment Income
4.6610.4710.75---
Other Non Operating Income (Expenses)
---11.492.011.85
EBT Excluding Unusual Items
-173.25-140.7-29.92-2.468.3444.01
Gain (Loss) on Sale of Investments
2.052.056.998.82.96-1.65
Pretax Income
-171.2-138.65-22.926.3411.342.36
Income Tax Expense
103.6381.83-4.023.835.039.21
Net Income
-274.83-220.47-18.92.516.2833.15
Net Income to Common
-274.83-220.47-18.92.516.2833.15
Net Income Growth
----60.02%-81.07%42.06%
Shares Outstanding (Basic)
605958575656
Shares Outstanding (Diluted)
605958585757
Shares Change
1.85%1.34%1.03%1.01%0.11%3.14%
EPS (Basic)
-4.59-3.74-0.330.040.110.60
EPS (Diluted)
-4.59-3.74-0.330.040.110.58
EPS Growth
----63.64%-81.03%38.09%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-139.96-110.44-20.48-88.2531.3163.66
Free Cash Flow Per Share
-2.34-1.87-0.35-1.530.551.12
Gross Margin
93.59%93.96%94.31%92.32%90.45%90.46%
Operating Margin
-77.59%-69.95%-20.46%-7.24%2.49%15.69%
Profit Margin
-119.87%-102.02%-9.51%1.30%2.47%12.34%
Free Cash Flow Margin
-61.05%-51.11%-10.30%-45.81%12.31%23.69%
EBITDA
-169.11-143.06-32.53-10.949.0645.01
EBITDA Margin
-73.76%-66.20%-16.36%-5.68%3.56%16.75%
D&A For EBITDA
8.88.118.133.012.732.84
EBIT
-177.91-151.17-40.66-13.956.3342.17
EBIT Margin
-77.59%-69.95%-20.46%-7.24%2.49%15.69%
Effective Tax Rate
---60.42%44.47%21.75%
Revenue as Reported
229.28216.11198.77192.64254.38268.68
SEC Filings: 10-K · 10-Q